Preferred Label : HIV-1 Protease Inhibitor ASC09;
NCIt synonyms : ((3aS,4R,6aR)-2,3,3a,4,5,6a-Hexahydrofuro(2,3-b)furan-4-yl) N-((1S,2R)-1-benzyl-3-((2-((1-cyclopentyl-4-piperidyl)amino)-1,3-benzothiazol-6-yl)sulfonyl-isobutyl-amino)-2-hydroxy-propyl)carbamate; Protease Inhibitor ASC09; Carbamic Acid, N-((1S,2R)-3-(((2-((1-cyclopentyl-4-piperidinyl)amino)-6-benzothiazolyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-,
(3R,3aS,6aR)-hexahydrofuro(2,3-b)furan-3-yl Ester;
NCIt related terms : TMC-310911;
NCIt definition : An orally bioavailable human immunodeficiency virus type 1 (HIV-1) protease inhibitor,
with potential activity against HIV and certain other RNA viruses. Upon oral administration,
HIV-1 protease inhibitor ASC09 selectively targets and binds to the active site of
HIV-1 protease, and inhibits the dimerization and catalytic activity of HIV-1 protease.
This inhibits the proteolytic cleavage of viral Gag and Gag-Pol polyproteins in HIV-infected
cells. This inhibition leads to the production of immature, non-infectious viral proteins
that are unable to form mature virions, and prevents HIV replication. In addition,
ASC09 may also inhibit viral proteases from other RNA viruses, thereby preventing
their replication.;
UNII : 0151W500HP;
InChIKey : JQUNFHFWXCXPRK-AMMMHQJVSA-N;
CAS number : 1000287-05-7;
Molecule name : ASC 09; TMC-310911; ASC-09; TMC 310911;
NCI Metathesaurus CUI : CL1406748;
Origin ID : C172635;
UMLS CUI : C5417927;
Currated CISMeF NLP mapping
- ((3aS,4R,6aR)-2,3,3a,4,5,6a-Hexahydrofuro(2,3-b)furan-4-yl) N-((1S,2R)-1-benzyl-3-((2-((1-cyclopentyl-4-piperidyl)amino)-1,3-benzothiazol-6-yl)sulfonyl-isobutyl-amino)-2-hydroxy-propyl)carbamate [MeSH concept]
- Semantic type(s)
- concept_is_in_subset
